Active — Not RecruitingNot Applicable

Evaluating Prenatal Exome Sequencing Study

Netherlands235 participantsStarted 2022-02-21

Plain-language summary

This study evaluates the impact of the various outcomes of pES (definitive diagnosis, probable diagnosis and IF) on clinical decision making and on parental psychological wellbeing, compared between different analysis strategies to investigate the clinical utility, defined as the balance between potential harms and benefits.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least one fetal anomaly detected in the current pregnancy, irrespective of gestational age; * Pregnancy ongoing; * Mother at least 18 years old and providing consent for pES; * If father is available: father at least 18 years old and providing consent for pES. Exclusion Criteria: There are no exclusion criteria.

What they're measuring

Percentage of definitive diagnoses, probable diagnoses and incidental findings (IF)

Timeframe: 2 years

Trial details

NCT IDNCT05290701

SponsorLeiden University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-10-01

View on ClinicalTrials.gov More Congenital Anomalies trials